Effect of neoadjuvant androgen deprivation therapy on prostate and tumor morphology prior to MRI-guided transurethral ultrasound ablation of prostate cancer.

Firmagon (degarelix) - Astellas, Ferring

Effect of neoadjuvant androgen deprivation therapy on prostate and tumor morphology prior to MRI-guided transurethral ultrasound ablation of prostate cancer. (PubMed, Int J Hyperthermia) - Sep 15, 2026 - P1 | "Short-term nADT with degarelix was associated with significant changes in prostate and tumor morphology. Future studies should determine whether these changes improve TULSA outcomes."
Journal • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

http://www.ncbi.nlm.nih.gov/pubmed/42733361

Ilari Virtanen; Mikael Anttinen; Mikael Högerman; Otto Ettala; Pertti Nurminen; Pietari Mäkelä; Teija Sainio

Sep 15, 2026